Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma | NEJM

Danmark Nyheder Nyheder

Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma | NEJM
Danmark Seneste Nyt,Danmark Overskrifter
  • 📰 medical_xpress
  • ⏱ Reading Time:
  • 68 sec. here
  • 3 min. at publisher
  • 📊 Quality Score:
  • News: 30%
  • Publisher: 51%

Monoclonal antibody reduces asthma attacks in urban youth NIAIDNews TheLancet

, which is available with the full text of this article at NEJM.org, was developed by the sponsor, GlaxoSmithKline. The first draft of the manuscript was written by the first author, an employee of GlaxoSmithKline; editorial support funded by GlaxoSmithKline was provided by Gardiner-Caldwell Communications. Data were collected by the investigators and analyzed by employees of the sponsor.

Exacerbations were confirmed by objective changes that patients recorded daily in an electronic diary .At each clinic visit, we evaluated results of spirometric and hematologic tests and administered the 5-item Asthma Control Questionnaire , on which scores range from 0 to 6, with higher scores indicating worse function, and 0.5 is the minimal clinically important difference between scores. At randomization and the final study visit, we administered the St.

Safety was evaluated by an assessment of adverse events, vital signs, electrocardiographic findings, and immunogenicity, along with clinical laboratory testing. Levels of antibodies against mepolizumab were measured before randomization and at three time points after randomization.All patients who received at least one dose of a study drug were included in a modified intention-to-treat analysis.

that included covariates for treatment, use of maintenance oral glucocorticoids, geographic region, number of exacerbations in the previous year, and baseline percentage of the predicted FEV. We estimated that with 180 patients in each group, the study would have a power of 90% to detect a 40% decrease in the exacerbation rate, from 2.40 per year in the placebo group to 1.44 per year in each of the mepolizumab groups, at a two-sided significance level of 0.05.

Vi har opsummeret denne nyhed, så du kan læse den hurtigt. Hvis du er interesseret i nyheden, kan du læse hele teksten her. Læs mere:

medical_xpress /  🏆 101. in UK

Danmark Seneste Nyt, Danmark Overskrifter

Similar News:Du kan også læse nyheder, der ligner denne, som vi har indsamlet fra andre nyhedskilder.

'I've been let down - I shouldn't have stage-4 cancer''I've been let down - I shouldn't have stage-4 cancer''This is an absolute disaster' Imperial College London's prof_price tells Newsnight delays in care is the worst cancer crisis she's seen in her lifetime. 📺 Full report tonight on BBC 2 at 22.30
Læs mere »

Huge new 'super salon' to open in Merseyside this yearHuge new 'super salon' to open in Merseyside this yearThe salon will feature luxury treatment rooms and a training school for VTCT laser and skin rejuvenation students 🙌
Læs mere »

The best tried and tested chickenpox treatmentsThe best tried and tested chickenpox treatmentsMother&Baby roundup the best Chickenpox This buyer’s guide includes who to spot chickenpox and the best over-the-counter treatments.
Læs mere »

Almost 90% of subjects who experience COVID-19-linked taste or smell dysfunction fully recover after two yearsAlmost 90% of subjects who experience COVID-19-linked taste or smell dysfunction fully recover after two yearsAlmost 90% of subjects who experience COVID-19-linked taste or smell dysfunction fully recover after two years UniPadova COVID19 Coronavirus SARSCoV2 Anosmia Smell Taste Dysfunction
Læs mere »

All the Watford dentists accepting NHS patientsAll the Watford dentists accepting NHS patientsAs nine in 10 NHS dentists in the UK stop accepting new adult patients, we've rounded up the Watford dentists that are.
Læs mere »



Render Time: 2025-04-03 17:13:25